Sign In
Buy LTRN
$2.75
+0.140 (+5.36%)
At Close: Aug 04, 2026
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
2 sub‑$10 AI stocks to outperform Palantir in 2026, according to ChatGPT‑5
02:58pm, Sunday, 23'rd Nov 2025
Palantir Technologies (NASDAQ: PLTR) has grown into a dominant force in AI-driven data analytics, securing lucrative government contracts and expanding its mission-critical intelligence business.
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
08:33pm, Thursday, 20'th Nov 2025
Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - Presid
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
01:11pm, Thursday, 13'th Nov 2025
Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Go
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
08:30am, Thursday, 13'th Nov 2025
DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
08:00am, Thursday, 06'th Nov 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET.
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.
DALLAS--(BUSINESS WIRE)--LP-284 at 25th LL&M Congress & CMR.
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
08:00am, Friday, 24'th Oct 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025.
DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184.
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
04:30pm, Wednesday, 13'th Aug 2025
DALLAS--(BUSINESS WIRE)--Q2 2025 Financial Results & Business Updates.
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Inves
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of it
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
07:30am, Thursday, 31'st Jul 2025
DALLAS--(BUSINESS WIRE)--Harmonic Trial - Japan Cohort Completion.
